What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The clinical trial evidence from the ASCLEPIOS I and II trials demonstrates that ofatumumab significantly reduces the number of relapses and slows disease progression compared to teriflunomide, with a notable annual relapse rate ratio of 0.50 and 0.42 in the respective trials. While there is no direct comparison with other treatments, indirect comparisons suggest comparable efficacy with other established therapies, indicating a clear clinical advantage.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates suggest that ofatumumab is a cost-effective option for treating relapsing-remitting multiple sclerosis, with ICERs falling within NICE’s acceptable thresholds. The committee concluded that the treatment represents an acceptable use of Healthcare resources, particularly when considering the commercial arrangement that provides a discount.
Is there quality-of-life evidence payers weigh? — Quality of life
The evidence indicates that ofatumumab is associated with a reduction in disability progression, which is likely to positively impact HRQoL. The committee noted that the ability to self-administer the treatment at home is a significant advantage, potentially leading to improved daily functioning and overall well-being for patients with relapsing multiple sclerosis.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Ofatumumab demonstrated a favorable safety profile in the ASCLEPIOS trials, with no unexpected safety concerns reported. The adverse events were manageable and comparable to existing therapies, indicating that the treatment is well-tolerated by patients.
Was the drug compared against what payers expect? — Comparator Selection
The primary evidence for ofatumumab comes from comparisons with teriflunomide, which is appropriate. However, the lack of direct comparisons with other therapies limits the robustness of the evidence. Indirect comparisons were made, but they introduce uncertainty due to reliance on single trials for many comparators.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population in the ASCLEPIOS studies is generally representative of the target population for ofatumumab, with a focus on adults with active relapsing-remitting multiple sclerosis. The committee noted that the evidence is applicable to the Healthcare population, although some subgroup analyses were deemed not robust enough for separate consideration.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Ofatumumab can be self-administered at home, which aligns well with current treatment pathways for multiple sclerosis. This ease of administration is likely to facilitate integration into existing healthcare delivery models without significant disruption.
Are the wider system costs understood? — Resource Use and Cost Implications
The overall resource implications of adopting ofatumumab are manageable, particularly given the cost-effectiveness findings. The treatment is expected to provide significant benefits relative to its costs, aligning with Healthcare budget considerations.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is supported by two phase 3 randomized controlled trials, which are robust and provide a strong foundation for the clinical effectiveness claims. However, some limitations in the indirect comparisons and subgroup analyses introduce minor concerns regarding the overall robustness.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are some uncertainties regarding the long-term effects and treatment sequencing, the overall context of unmet need in relapsing-remitting multiple sclerosis and the favorable cost-effectiveness profile mitigate these concerns. The committee found the treatment’s benefits to outweigh the uncertainties.
